sector medic suppli devic
reason jump ship
messag edward result mix bag soft tavr number stole
spotlight overal top bottom line beat tavr perform
disappoint market quarterli up decad
case histor think overreact latest data point would
mistak take perform total estim actual move
modestli higher today lower dcf-deriv pt
continu see meaning upsid potenti stock
lumpi tavr growth strike global tavr sale cc came
consensu manag elect provid revenu split
geographi math suggest sale actual fell shi street
roughli ceo mike mussallem describ perform line
compani expect certainli repres departur recent trend
saw edward grow tavr sale overal solid
growth may dip mr mussallem point possibl
procedur pull forward time seen surprisingli strong
impact holiday one less sell day quarter tough
yoy comp growth reduc contribut
royalti expect add less edward top line rate reset
begin year cumul impact headwind difficult
calcul believ least partial explain quarter subpar perform
importantli manag maintain guidanc full year ww tavr revenu
come high end origin rang outlook continu view
achiev even take slower expect start account
intern edward turn solid tavr perform estim ou
sale came cc consensu edward
note eu share modestli rel expect compani
regain momentum recent launch centera valv roll sapien ultra
ce mark come market centera particularli intrigu view give
edward premium offer eu market use self-expand valv
today believ price sensit certain account could limit compani
opportun share gain fraction total model mere assum
stabil edward share go forward leav outright gain sourc
potenti upsid clinic front fda approv sapien ultra still expect
yearend centera pivot studi slate begin enrol meanwhil
edward portfolio transcathet mitral tricuspid technolog continu move
toward commerci well ce mark cardioband tricuspid posit still
expect pascal edge-to-edg system track follow
outsid transcathet valv heart valv therapi critic
sourc upsid quarter revenu rose cc
consensu edward aortic valv volum continu feel pressur rise
tavr penetr sale benefit on-going posit mix shift
continu roll-out inspiri resilia valv europ resilia launch kick
januari entri japan still slate later year pend reimburs
approv continu believ ramp tavr adopt repres headwind
eventu appli signific pressur surgic valv busi remain
encourag edward abil innov tri stay ahead wave long
possibl manag continu expect sale come high
end guidanc rang model call revenu
cc continu page
page analyst certif import disclosur
critic system report sale rise cc top consensu
beat driven strong growth across portfolio led
hemospher next-gen advanc monitor platform asia pacif
manag continu expect full year sale come high end
initi guidanc rang model call revenu
top line solid expens control help off-set weak gross margin
allow revenu upsid fall edward report gross margin
yoy consensu posit product mix partial off-set
fx hedg expens relat closur compani swiss manufactur
facil would note consensu forecast struck us somewhat aggress
head print model call quarter featur
bigger headwind currenc year sg spend fell yoy
came street expect expens decreas
sale consensu combin drove ebita margin
yoy still street project despit gm miss
final lower expect tax rate vs ad earn
back result manag took ep guidanc
edward expect full year adjust ep
previous origin outlook laid compani decemb analyst
meet total revenu still forecast high end manag origin
rang lower expect tax rate help boost profit model
call adjust ep total revenu
organ compar prior estim respect
long-term confid edward growth runway remain unchang
tavr market quarterli up down past investor
histor well-serv look short-term lumpi focus
bigger pictur front tuesday result noth alter view market
remain well-posit sustain growth especi ahead like expans
low risk popul next year edward compani remain track deliv
anoth year top bottom line growth yet base
trade aftermarket could open wednesday modest premium mani
large-cap med-tech peer far lower growth trajectori think near-term
retrench stock warrant recent run sinc vs
 admittedli mix point inclin view
meaning weak buy opportun lower dcf-deriv
price target take account revis estim recent
interest rate fluctuat signific upsid potenti target current level
reiter buy rate ew share
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track least doubl next five year edward pois primari
beneficiari growth even competit increas meanwhil compani robust
pipelin potenti extend growth runway well next decad view
emerg opportun expand tavr applic beyond sever
symptomat aortic stenosi popul develop equal compel new market
transcathet treatment mitral tricuspid valv diseas visibl new
growth driver improv expect investor confid edward long-term growth
potenti increas support premium valuat stock
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat also make
compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv price target assum
wacc termin growth rate calcul forward npv per share
previous equat multipl previous
forward ntm ep estim signific upsid potenti
price target current level assign edward buy rate
downsid risk rate price target includ tavr market growth fall
short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
